Oxaliplatin–Biomimetic Magnetic Nanoparticle Assemblies for Colon Cancer-Targeted Chemotherapy: An In Vitro Study
by
Ylenia Jabalera 1,†
, Beatriz Garcia-Pinel 2,3,4,†, Raul Ortiz 2,3,4, Guillermo Iglesias 1, Laura Cabeza 2,3,4, José Prados 2,3,4,*, Concepcion Jimenez-Lopez 1,* and Consolación Melguizo 2,3,4
, Beatriz Garcia-Pinel 2,3,4,†, Raul Ortiz 2,3,4, Guillermo Iglesias 1, Laura Cabeza 2,3,4, José Prados 2,3,4,*, Concepcion Jimenez-Lopez 1,* and Consolación Melguizo 2,3,4
1
Department of Microbiology, Sciences School, University of Granada, Campus de Fuentenueva, 18002 Granada, Spain
2
Institute of Biopathology and Regenerative Medicine (IBIMER), Center of Biomedical Research (CIBM), University of Granada, 18100 Granada, Spain
3
Department of Anatomy and Embriology, Faculty of Medicine, University of Granada, 18071 Granada, Spain
4
Instituto de Investigación Biosanitaria IBS.GRANADA, 18012 Granada, Spain
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Pharmaceutics 2019, 11(8), 395; https://doi.org/10.3390/pharmaceutics11080395
Received: 6 June 2019 / Revised: 30 July 2019 / Accepted: 1 August 2019 / Published: 6 August 2019
(This article belongs to the Special Issue Nanopharmaceuticals for Image-Guided Cancer Therapy and Diagnosis)
Conventional chemotherapy against colorectal cancer (CRC), the third most common cancer in the world, includes oxaliplatin (Oxa) which induces serious unwanted side effects that limit the efficiency of treatment. Therefore, alternative therapeutic approaches are urgently required. In this work, biomimetic magnetic nanoparticles (BMNPs) mediated by MamC were coupled to Oxa to evaluate the potential of the Oxa–BMNP nanoassembly for directed local delivery of the drug as a proof of concept for the future development of targeted chemotherapy against CRC. Electrostatic interactions between Oxa and BMNPs trigger the formation of the nanoassembly and keep it stable at physiological pH. When the BMNPs become neutral at acidic pH values, the Oxa is released, and such a release is greatly potentiated by hyperthermia. The coupling of the drug with the BMNPs improves its toxicity to even higher levels than the soluble drug, probably because of the fast internalization of the nanoassembly by tumor cells through endocytosis. In addition, the BMNPs are cytocompatible and non-hemolytic, providing positive feedback as a proof of concept for the nanoassembly. Our study clearly demonstrates the applicability of Oxa–BMNP in colon cancer and offers a promising nanoassembly for targeted chemotherapy against this type of tumor.
View Full-Text
Keywords:
colon carcinoma; magnetite nanoparticles; MamC; magnetotactic bacteria; nanocarriers; oxaliplatin
▼
Show Figures
Graphical abstract
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
MDPI and ACS Style
Jabalera, Y.; Garcia-Pinel, B.; Ortiz, R.; Iglesias, G.; Cabeza, L.; Prados, J.; Jimenez-Lopez, C.; Melguizo, C. Oxaliplatin–Biomimetic Magnetic Nanoparticle Assemblies for Colon Cancer-Targeted Chemotherapy: An In Vitro Study. Pharmaceutics 2019, 11, 395.
Show more citation formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
- Supplementary File 1:
Supplementary (PDF, 447 KB)
